胃肠间质瘤免疫疗法及新策略的研究进展

Advances in immunotherapy and new strategies for gastrointestinal stromal tumor

胃肠道间质瘤(CIST)是源自Cajal间质细胞的软组织肿瘤,是胃肠道肉瘤的一种常见类型。靶向药物的发现大大提高了GIST的生存率,而伊马替尼作为靶向药物,已经成为GIST的一线治疗药物。然而,最近研究发现,大多数患者已经对伊马替尼产生了耐药性。最新的研究表明,免疫疗法,包括基于免疫检查点抑制剂和伊马替尼联合疗法、细胞因子、抗KIT抗体、双特异性单克隆抗体疗法和其他新型策略,对治疗胃肠道间质瘤也是有效的。在本综述中,将讨论免疫疗法和其他新策略在治疗胃肠道间质瘤中的作用.

Gastrointestinal stromal tumors(GIST),soft tissue tumors derived from Cajal stromal cells,are a common type of gastrointestinal sarcoma.The discovery of targeted drugs has greatly improved the survival rate of GIST,and imatinib,as a targeted drug,has become the first-line treatment for GIST.However,recent studies have found that most patients have developed resistance to imatinib.Recent studies have shown that immunotherapy,including combination therapy based on immune checkpoint inhibitors and imatinib,cytokines,anti-kit antibodies,bisspecific monoclonal antibody therapy,and other novel strategies,are also effective in treating gastrointestinal stromal tumors.In this review,the role of immunotherapy and other novel strategies in the treatment of gastrointestinal stromal tumors will be discussed.